MARKET

MDCX

MDCX

Medicus Pharma Ltd
NASDAQ
1.060
+0.067
+6.74%
After Hours: 1.050 -0.01 -0.96% 18:55 02/13 EST
OPEN
0.9900
PREV CLOSE
0.9931
HIGH
1.160
LOW
0.9800
VOLUME
580.38K
TURNOVER
--
52 WEEK HIGH
8.94
52 WEEK LOW
0.9174
MARKET CAP
26.62M
P/E (TTM)
-0.5373
1D
5D
1M
3M
1Y
5Y
1D
Medicus Pharma CEO Highlights AI-Driven Drug Development on Bloomberg
Reuters · 1d ago
Medicus Pharma Wins FDA Go-Ahead for Phase 2b Teverelix Trial in High-Risk Prostate Cancer
TipRanks · 3d ago
Medicus signs six-part media series with New to the Street
TipRanks · 3d ago
Medicus receives FDA ‘study may proceed’ clearance for Teverelix Phase 2b study
TipRanks · 3d ago
Medicus Pharma Receives FDA Clearance to Proceed with Teverelix Phase 2b Study
Reuters · 3d ago
MEDICUS PHARMA RECEIVES FDA “STUDY MAY PROCEED” CLEARANCE FOR TEVERELIX® PHASE 2B STUDY IN ADVANCED PROSTATE CANCER PATIENTS WITH HIGH CARDIOVASCULAR RISK
Reuters · 3d ago
Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk
Barchart · 3d ago
Weekly Report: what happened at MDCX last week (0202-0206)?
Weekly Report · 4d ago
More
About MDCX
Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. SkinJect Inc., a wholly owned subsidiary of the Company, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. It is conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. It has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the UAE. Its subsidiary, Antev Limited, is a late clinical stage biotech company, developing Teverelix, a GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse episodes due to enlarged prostate.

Webull offers Medicus Pharma Ltd stock information, including NASDAQ: MDCX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDCX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MDCX stock methods without spending real money on the virtual paper trading platform.